Reuters logo
BRIEF-Medivir reports positive data in remetinostat phase II trial ‍​
October 13, 2017 / 10:54 AM / 2 months ago

BRIEF-Medivir reports positive data in remetinostat phase II trial ‍​

Oct 13 (Reuters) - Medivir Ab ‍​

* Medivir says ‍remetinostat phase ii data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage mf-type ctcl​

* phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below